drugset / Trial / NCT02946034

Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C

NCT02946034

Phase 4 Completed 10 enrolled Massachusetts General Hospital AbbVie · collab
NaSingle-groupOpen-labelTreatment

Summary

Open-label experimental trial of 12 weeks of Viekira Pak treatment ± ribavirin or Mavyret for adults with chronic kidney disease and hepatitis C.

Timeline

Start
2017-02-01
Primary completion
2020-09-16
Completion
2020-09-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Ribavirin Small molecule
Subject dasabuvir Small molecule
Subject glecaprevir Other / unclassified